How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,908 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch ChildCAPTURE registry. (Abstract)

The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch ChildCAPTURE registry. Scalp psoriasis can be a physical and psychological burden for patients irrespective of overall psoriasis severity and is difficult to treat. Studies on scalp psoriasis in children and potential associations with clinical characteristics are sparse. In children, the scalp is commonly reported as the initial site of presentation (...) and scalp psoriasis tends to develop more frequently in girls than in boys. One multicenter study reported scalp psoriasis more frequently in severe psoriasis versus moderate psoriasis but the finding did not reach statistical significance. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

82. Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis. (Abstract)

Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis. We investigated the prevalence of liver fibrosis in psoriatic patients and evaluated the factors associated with liver fibrosis in this population. We enrolled 112 patients with psoriasis aged of 18 years or older. We excluded pregnant women, patients with known liver diseases, heavy alcohol drinkers and regular users of hepatotoxic medications other than methotrexate. Psoriasis (...) was defined as severe in following conditions: PASI≥10, or generalized pustular, erythrodermic or arthropathic psoriasis, or requirement of a systemic medication. Anthropometric measurements were performed. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

83. The top ten research priorities for psoriasis in the UK; results of a James Lind Alliance psoriasis priority setting partnership. Full Text available with Trip Pro

The top ten research priorities for psoriasis in the UK; results of a James Lind Alliance psoriasis priority setting partnership. Psoriasis is an immune-mediated inflammatory skin disease, with a prevalence of 0·09% to 11·4%, which affects approximately two million people in the U.K.1,2 It has a significant psychological and social impact on affected individuals, is associated with co-morbidities such as depression, cardiovascular disease and inflammatory arthritis, and confers a substantial (...) economic burden on the National Health Service.1-3 Access to appropriate care that addresses the high health-care burden and complex interlinked physical, psychological and social needs of those who have psoriasis is often poor. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

84. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Full Text available with Trip Pro

Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). The 'treat to target' paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis.To identify treatment targets in psoriasis using two common measures of disease activity: Psoriasis Area and Severity Index (PASI) and Physician's (...) Global Assessment (PGA).Data from a multicentre longitudinal U.K. cohort of patients with psoriasis receiving systemic or biologic therapies (British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) were used to identify absolute PASI thresholds for 90% (PASI 90) and 75% (PASI 75) improvements in baseline disease activity, using receiver operating characteristic curves. The relationship between PGA (clear, almost clear, mild, moderate, moderate-severe, severe) and PASI

2019 British Journal of Dermatology

85. Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question-naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris. Full Text available with Trip Pro

Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question-naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris. Chronic pruritus is a bothersome symptom in psoriasis vulgaris and can profoundly reduce quality of life (QoL). In this exploratory analysis of the PSORITUS study, the impact of pruritus on QoL in 130 subjects with moderate-to-severe psoriasis was assessed using the ItchyQoL questionnaire. The majority of patients (n = 127) had to scratch their itchy (...) questionnaire as a validated tool responsive to treatment for detailed insights into chronic pruritus in patients with psoriasis.

2019 Acta Dermato-Venereologica

86. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. Full Text available with Trip Pro

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. Objective: Biologic therapies have dramatically changed the management of moderate to severe psoriasis; however, few US real-world studies characterize the unmet needs of patients who do not respond to biologic therapies. This study examined the characteristics at enrollment of patients with moderate to severe (...) psoriasis who had insufficient responses to anti-tumor necrosis factor therapies (anti-TNFs). Methods: Patients enrolled in the Corrona Psoriasis Registry from April 2015 to June 2018 who initiated an anti-TNF at enrollment were stratified on the basis of body surface area (BSA) improvement to <3% or a 75% improvement from enrollment to the 6-month follow-up visit (response versus insufficient response). Patient demographics and disease characteristics were described at enrollment, and changes

2019 Journal of Dermatological Treatment

87. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Full Text available with Trip Pro

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world's population. In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light-based therapies, which include narrowband and broadband UVB, UVA in conjunction (...) with photosensitizing agents, targeted UVB treatments such as with an excimer laser, and several other modalities and variations of these core phototherapies, including newer applications of pulsed dye lasers, intense pulse light, and light-emitting electrodes. We will provide an in-depth, evidence-based discussion of efficacy and safety for each treatment modality and provide recommendations and guidance for the use of these therapies alone or in conjunction with other topical and/or systemic psoriasis

2019 Journal of American Academy of Dermatology

88. Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. Full Text available with Trip Pro

Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be mis-categorized, which can lead (...) to under-treatment of psoriasis.To develop a consensus statement on the classification of psoriasis severity.A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity.After completion of the exercise, seven severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy

2019 Journal of American Academy of Dermatology

89. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. (Abstract)

Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. Psoriasis is a chronic dermatologic disease affecting 2% of the general population. Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a newly defined member of the TNF family. Increased serum levels of TWEAK were reported in inflammatory diseases. The relationship between serum (...) TWEAK levels and severity of psoriasis has not yet been proven. Our aim was to clarify the change in serum TWEAK levels in response to conventional and anti-TNF treatments.Blood samples were collected from 103 moderate or severe chronic plaque psoriasis patients with or without arthritis who were referred to the Department of Dermatology, Istanbul University Cerrahpasa Medical Faculty between the years 2016 and 2018. Psoriasis Area and Severity Index (PASI) scores were calculated, and serum TWEAK

2019 International Journal of Dermatology

90. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Full Text available with Trip Pro

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Objective: This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting. Research design and methods: All psoriatic patients starting secukinumab between January 2016 and February 2017 in 11 European centers were followed until (...) February 2018 and retrospectively evaluated. Main outcome measures: Secukinumab effectiveness was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) and absolute PASI score modifications throughout 52 weeks of therapy. Additionally measures assessing effectiveness were used, including improvements of body surface area (BSA) and Dermatology Life Quality Index (DLQI). Results: Out of the 330 patients with potentially 52-week treatment duration, naïve to biologics

2019 Journal of Dermatological Treatment

91. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. Full Text available with Trip Pro

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. This analysis examined the association between psoriasis severity, assessed by body surface area (BSA) and the Investigator's Global Assessment (IGA; previously used only in clinical trials), and patient-reported outcomes (PROs) in a real-world setting.Cross-sectional analysis within the Corrona Psoriasis (...) Registry, an independent, prospective registry.70 dermatology practices in the USA.1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.Psoriasis severity was assessed by percentage of affected BSA (mild (0%-5%), moderate (>5%-10%), severe (>10%-15%), very severe (>15%)) and IGA scores (clear/almost clear (0-1), mild (2), moderate (3), severe (4)). PROs (pain, itch, fatigue; Dermatology Life Quality Index [DLQI]; EuroQoL Visual

2019 BMJ open

92. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Full Text available with Trip Pro

A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. Herpes zoster (HZ) incidence is linked to immunosuppression. Patients with psoriasis or psoriatic arthritis (PsA) on systemic therapy might be at an increased risk for HZ.To assess HZ risk in patients with psoriasis and PsA by systemic treatment and provide (...) recommendations regarding HZ vaccination.A systematic literature search was performed for HZ in patients with psoriasis and PsA. HZ vaccination guidelines were reviewed, and the medical board of the National Psoriasis Foundation made consensus recommendations in psoriasis and PsA patients using graded evidence.In total, 41 studies met inclusion criteria. Systemic corticosteroids (strong, 1), tofacitinib (strong, 1), and combination therapy with biologic and conventional synthetic disease-modifying

2019 Journal of American Academy of Dermatology

93. Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. (Abstract)

Challenges in the treatment of psoriasis with biologics: vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. Biologics are potent immunomodulatory drugs, whose application in the treatment of psoriasis has shown extremely good therapeutic results and a satisfactory safety profile. The administration of these agents in special cases, such as in patients with HIV infection, previous malignancy, unclear vaccination status as well as children

2019 International Journal of Dermatology

94. Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. (Abstract)

Biological treatments for paediatric psoriasis (BiPe): A retrospective observational study on biological drug survival in daily practice in childhood psoriasis. Three biotherapies - etanercept, adalimumab and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long-term performance in real-life settings.The objective of this study was to evaluate the survival (...) rates of biological therapies in children with psoriasis in real-life conditions. Secondary objectives were to evaluate the factors associated with the choice of the biological therapy and to report severe adverse events.This study was an observational retrospective study. Data were extracted from the clinical records of 134 children. Kaplan-Meier estimates were used to analyse drug survival overall and in subgroups of plaque psoriasis, bio-naïve and non-naïve patients.We analysed 184 treatment

2019 Journal of the European Academy of Dermatology and Venereology

95. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. Full Text available with Trip Pro

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry.Eligible patients aged ≥ 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit

2019 Journal of Dermatological Treatment

96. Long-term maintenance of secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. (Abstract)

Long-term maintenance of secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. There is limited data regarding the long-term persistence of biological therapy in patients with psoriasis. In particular, reasons of secukinumab discontinuation have not been thoroughly investigated.To better ascertain the real life maintenance of secukinumab in psoriasis, we conducted a retrospective study to evaluate the incidence, causes and factors of secukinumab (...) discontinuation in patients with psoriasis.All patients treated with secukinumab for psoriasis in the dermatology department of Toulouse, France, between September 2011 and June 2017, were included.Among 91 patients included; 22 (24, 2%) patients discontinued secukinumab. In 14 (15%) patients, the discontinuation was due to loss of efficacy. Two patients stopped treatment because of a desire for pregnancy, five patients due to the occurrence of adverse events. A longer disease duration (p = 0,01

2019 Clinical & Experimental Dermatology

97. Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. Full Text available with Trip Pro

Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. Psoriasis in children can be a challenging diagnosis: the clinical presentation is often more subtle, may occur in covered sites and can be an unexpected diagnosis as psoriasis if often thought to occur at older ages. Poor recognition and delayed diagnosis of psoriasis in children can lead to inadequate treatment and lack of monitoring

2019 British Journal of Dermatology

98. [Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)]

[Secukinumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue wissenschaftliche erkenntnisse); dossierbewertung [Secukinumab (plaque (...) psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (plaque-psoriasis): nutzenbewertung gemäß § 35a SGB V (neue

2017 Health Technology Assessment (HTA) Database.

99. [Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V]

[Ixekizumab (plaque psoriasis) - benefit assessment according to õ35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07 [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ixekizumab (Plaque Psoriasis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-07. [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V] Cologne

2017 Health Technology Assessment (HTA) Database.

100. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08]

[Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31 [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Secukinumab (Plaque-Psoriasis): Addendum zum Auftrag A17-08; Auftrag A17-31. [Secukinumab (plaque psoriasis) - addendum to Commission A17-08] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 529. 2017 Final publication URL Indexing Status Subject indexing

2017 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>